guttitude logo

guttitude

early access
Get Checklistguttitude Pro
← Back to atlas
supportedmidmoderate inflation risk

Subdoligranulum

type 2 diabetes

Subdoligranulum is an interesting but still moderate-confidence signal in type 2 diabetes.

Subdoligranulum shows a moderate evidence base in type 2 diabetes, with multiple central papers and additional supporting literature.

subdoligranulum
Credibility score
36
Human translation
5/5
Reproducibility
3/5
Novelty
3/5
Actionability
3/5
Credibility 36Human translation 5/5Reproducibility 3/5Novelty 3/5Actionability 3/5
Why this scores the way it does
  • moderate central evidence base
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

13 papers
[Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
2019
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Single-Anastomosis Duodenal Jejunal Bypass Improve Glucose Metabolism by Regulating Gut Microbiota and Short-Chain Fatty Acids in Goto-Kakisaki Rats.
2020
Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Dairy product intake modifies gut microbiota composition among hyperinsulinemic individuals.
2021
European journal of nutrition
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes.
2020
Journal of diabetes research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India.
2021
Genome medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Habitual Dietary Intake Affects the Altered Pattern of Gut Microbiome by Acarbose in Patients with Type 2 Diabetes.
2021
Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbiota Composition and Fecal Metabolic Profiling in Patients With Diabetic Retinopathy.
2021
Frontiers in cell and developmental biology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome-Associated Gut Microbiome.
2022
International journal of molecular sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The fecal microbiotas of women of Pacific and New Zealand European ethnicities are characterized by distinctive enterotypes that reflect dietary intakes and fecal water content.
2023
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations in the Gut Microbiota in Pregnant Women with Pregestational Type 2 Diabetes Mellitus.
2023
mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbiota in Patients with Non-Alcoholic Fatty Liver Disease without Type 2 Diabetes: Stratified by Body Mass Index.
2024
International journal of molecular sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
β-Glucan Alone or Combined with Lactobacillus acidophilus Positively Influences the Bacterial Diversity and Metabolites in the Colonic Microbiota of Type II Diabetic Patients.
2025
Probiotics and antimicrobial proteins
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Association of gut microbiota and short-chain fatty acids with pre-diabetes and diabetes following gestational diabetes.
2026
Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Preclinical supporting evidence

3 papers
Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling.
2018
Frontiers in physiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients.
2022
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Exploring the Association between Citrus Nutraceutical Eriocitrin and Metformin for Improving Pre-Diabetes in a Dynamic Microbiome Model.
2023
Pharmaceuticals (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

3 papers
Gut microbiota profiles in two New Zealand cohorts with overweight and prediabetes: a Tū Ora/PREVIEW comparative study.
2023
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
A systematic review on gut microbiota in type 2 diabetes mellitus.
2024
Frontiers in endocrinology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies.
2025
Renal failure
Relevant review or meta-analysis for the signal-disease area.